A study in Scotland used C-peptide as an indicator of retained secretory capacity where T1D had been diagnosed initially, enabling re-categorization to T2D or monogenic diabetes, discontinuation of insulin therapy and provision of more appropriate antidiabetic therapy [36]. The gene discussed is INS; the disease is type 2 diabetes mellitus.